To include your compound in the COVID-19 Resource Center, submit it here.

Lorcaserin: Additional Phase III data

Arena reported data from a modified intent-to-treat (mITT) last observation carried forward (LOCF) analysis of 7,500 obese and overweight patients with or without diabetes from the Phase III BLOOM, BLOSSOM and BLOOM-DM trials of lorcaserin showing that the compound led to significant weight loss from baseline to week 52 vs. placebo. Specifically, 40.6% and

Read the full 549 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE